The development of semaglutide, a key ingredient in certain medicines, has transformed its maker, Novo Nordisk, into Europe’s most valuable company, with profound implications for Denmark, its home country. Novo’s market capitalization, exceeding $570 billion, surpasses the Danish economy. Its philanthropic foundation is now the world’s largest,